Reported Tuberculosis in the United States, 2017

Return to Main Menu

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 20151

Table 50. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2015
Reporting Area Total Cases with Therapy Extended2,3 Reasons Therapy was Extended
Rifampin Resistance Adverse Event Non-Adherence Treatment Failure Clinically Indicated Other
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
United States 829 55 (6.6) 155 (18.7) 94 (11.3) 9 (1.1) 325 (39.2) 302 (36.4)
Alabama 15 0 (0) 0 (0) 2 (13.3) 1 (6.7) 11 (73.3) 2 (13.3)
Alaska 8 1 (12.5) 3 (37.5) 1 (12.5) 0 (0) 1 (12.5) 3 (37.5)
Arizona 13 3 (23.1) 2 (15.4) 3 (23.1) 0 (0) 2 (15.4) 4 (30.8)
Arkansas 10 0 (0) 1 (10.0) 7 (70.0) 0 (0) 1 (10.0) 1 (10.0)
California 212 17 (8.0) 57 (26.9) 17 (8.0) 2 (0.9) 79 (37.3) 70 (33.0)
Colorado 4 0 (0.0) 1 (25.0) 0 (0) 0 (0) 2 (50.0) 1 (25.0)
Connecticut 5 1 (20.0) 1 (20.0) 0 (0) 0 (0) 3 (60.0) 4 (80.0)
Delaware 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100.0)
District of Columbia 5 0 (0) 1 (20.0) 2 (40.0) 0 (0) 3 (60.0) 0 (0)
Florida 30 3 (10.0) 4 (13.3) 3 (10.0) 0 (0) 17 (56.7) 6 (20.0)
Georgia 31 2 (6.5) 5 (16.1) 3 (9.7) 0 (0) 11 (35.5) 16 (51.6)
Hawaii 5 0 (0) 2 (40.0) 0 (0) 0 (0) 1 (20.0) 2 (40.0)
Idaho 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
Illinois 20 1 (5.0) 4 (20.0) 0 (0) 0 (0) 7 (35.0) 9 (45.0)
Indiana 4 1 (25.0) 0 (0) 1 (25.0) 0 (0) 1 (25.0) 1 (25.0)
Iowa 4 0 (0) 1 (25.0) 0 (0) 0 (0) 3 (75.0) 0 (0)
Kansas 4 0 (0) 0 (0) 0 (0) 0 (0) 1 (25.0) 3 (75.0)
Kentucky 10 0 (0) 1 (10.0) 1 (10.0) 0 (0) 5 (50.0) 7 (70.0)
Louisiana 9 0 (0) 3 (33.3) 1 (11.1) 0 (0) 5 (55.6) 0 (0)
Maine 1 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Maryland 23 0 (0) 2 (8.7) 1 (4.3) 0 (0) 12 (52.2) 9 (39.1)
Massachusetts 29 0 (0) 1 (3.4) 0 (0) 0 (0) 15 (51.7) 13 (44.8)
Michigan 5 0 (0) 2 (40.0) 0 (0) 0 (0) 2 (40.0) 3 (60.0)
Minnesota 10 1 (10.0) 4 (40.0) 1 (10.0) 0 (0) 3 (30.0) 2 (20.0)
Mississippi 5 0 (0) 1 (20.0) 0 (0) 0 (0) 2 (40.0) 3 (60.0)
Missouri 5 0 (0) 0 (0) 0 (0) 0 (0) 1 (20.0) 4 (80.0)
Montana 1 1 (100.0) 0 (0) 0 (0) 0 (0) 1 (100.0) 1 (100.0)
Nebraska 0 0 0 0 0 0 0
Nevada 6 0 (0) 1 (16.7) 0 (0) 0 (0) 2 (33.3) 3 (50.0)
New Hampshire 1 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0.0)
New Jersey 31 3 (9.7) 9 (29.0) 2 (6.5) 0 (0) 4 (12.9) 18 (58.1)
New Mexico 1 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
New York State4 7 1 (14.3) 1 (14.3) 0 (0) 0 (0) 3 (42.9) 4 (57.1)
New York City 35 2 (5.7) 5 (14.3) 4 (11.4) 2 (5.7) 6 (17.1) 16 (45.7)
North Carolina 19 5 (26.3) 7 (36.8) 4 (21.1) 0 (0) 1 (5.3) 5 (26.3)
North Dakota 0 0 0 0 0 0 0
Ohio 14 1 (7.1) 1 (7.1) 0 (0) 1 (7.1) 7 (50.0) 4 (28.6)
Oklahoma 5 0 (0) 2 (40.0) 2 (40.0) 0 (0) 0 (0) 1 (20.0)
Oregon 6 0 (0) 0 (0) 2 (33.3) 0 (0) 4 (66.7) 0 (0)
Pennsylvania 32 2 (6.3) 19 (59.4) 5 (15.6) 2 (6.3) 15 (46.9) 8 (25.0)
Rhode Island 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0)
South Carolina 7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7 (100.0)
South Dakota 4 0 (0) 1 (25.0) 0 (0) 0 (0) 1 (25.0) 2 (50.0)
Tennessee 5 0 (0) 1 (20.0) 0 (0) 0 (0) 2 (40.0) 4 (80.0)
Texas 136 3 (2.2) 2 (1.5) 25 (18.4) 1 (0.7) 77 (56.6) 43 (31.6)
Utah 3 2 (66.7) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0)
Vermont 0 0 0 0 0 0 0
Virginia 15 1 (6.7) 3 (20.0) 2 (13.3) 0 (0) 6 (40.0) 5 (33.3)
Washington 13 1 (7.7) 0 (0) 4 (30.8) 0 (0) 2 (15.4) 6 (46.2)
West Virginia 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
Wisconsin 12 1 (8.3) 6 (50.0) 1 (8.3) 0 (0) 5 (41.7) 3 (25.0)
Wyoming 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100.0)
American Samoa5 0 0 0 0 0 0 0
Fed. States of Micronesia5 3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100.0)
Guam5 2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0)
Marshall Islands5 7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 7 (100.0)
N. Mariana Islands5 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100.0)
Puerto Rico5 7 1 (14.3) 1 (14.3) 1 (14.3) 0 (0) 3 (42.9) 1 (14.3)
Republic of Palau5 2 0 (0) 0 (0) 0 (0) 0 (0) 1 (50.0) 1 (50.0)
U.S. Virgin Islands5 0 0 0 0 0 0 0

1 Most recent year for which data are available.
2 Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.
3 Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).
4 Excludes New York City.
5 Not included in U.S. totals.
Note: Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.

Page last reviewed: October 22, 2018